Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: serotonin 6 receptor antagonists - Suven Life Sciences

Drug Profile

Research programme: serotonin 6 receptor antagonists - Suven Life Sciences

Alternative Names: 5HT6 compounds; SUVN-501; SUVN-504; SUVN-507; SUVN-512; SUVN-623; SUVN-901; SUVN-976

Latest Information Update: 03 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suven Life Sciences
  • Class Antidementias; Antiparkinsonians; Antipsychotics; Carbazoles; Indoles; Neuroprotectants; Obesity therapies; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cognition disorders; Huntington's disease; Parkinson's disease; Schizophrenia
  • No development reported Obesity

Most Recent Events

  • 22 Aug 2018 Suven Life Sciences has patent protection corresponding to new chemical entities covering the class of selective 5-HT6 compounds for the treatment of neurodegenerative disorders in Canada and USA
  • 12 Jun 2018 Suven Life Sciences has patent protection for 5-HT4 and 5-HT6 compounds in China and USA
  • 22 May 2018 Suven Life Sciences secures product patents for 5-HT6 compounds in Norway and New Zealand
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top